Photodynamic therapy in gynaecological neoplastic diseases.
Since 1982, our department has used photodynamic therapy (PDT) in the treatment of loco-regional recurrences of gynaecological cancers. We have treated 26 patients in this time. In the majority of cases the site of vaginal recurrences was the vaginal vault. The light sources were an Argon-dye laser (Meditec) and, in some cases, a CO2 laser. The light dose ranged between 60 and 500 J cm-2. The photosensitizing drug used was Hematoporphyrin (HP) (Monico Farmaceutici) at the dose of 5 mg kg-1 body weight. Patients were evaluated 45 days after the treatment with a gynaecological examination and after 75-90 days with a vaginal smear. The results were divided into 2 groups: objective and symptomatic. The symptomatic response concerned only the patients treated with a palliative aim and, in this case, a complete response (CR) was a complete absence of symptoms at least for 60 days. In this group the complete response rate was 66%. In the curative group, the complete response was a cytological and/or histological absence of lesions. In this group we had 12 CR (70.58%). The survival rate was also evaluated. A significant review of the photodynamic therapy in gynaecological neoplasms has also been done.
Corti
L
L
Department of Radiotherapy, General Hospital, Padua, Italy.
Mazzarotto
R
R
Belfontali
S
S
De Luca
C
C
Baiocchi
C
C
Boso
C
C
Calzavara
F
F
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000369:Aged, 80 and over; D002278:Carcinoma in Situ / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006415:Hematoporphyrins / Q000627:therapeutic use; D006801:Humans; D007834:Lasers; D008875:Middle Aged; D010778:Photochemotherapy; D014625:Vaginal Neoplasms / Q000188:drug therapy
D006415:Hematoporphyrins